Clinical Trial: SWOG CCTG-PR26

SWOG CCTG-PR26

Status: New, Open

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)

Eligible for screening study DCP 001